What is the difference between Leqvio and Repatha? - Drugs. com Both Leqvio and Repatha are injectable medicines used to lower low density lipoprotein (LDL) cholesterol levels (also referred to as "bad cholesterol") While they target the same protein (PCSK9), they work differently to help your body manage cholesterol levels
label - accessdata. fda. gov The data described below reflect exposure to REPATHA in 8 placebo-controlled trials that included 2651 patients treated with REPATHA, including 557 exposed for 6 months and 515 exposed for 1
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for . . . This need is heightened by the latest 2025 ACC AHA Joint Committee Clinical Practice Guideline for the Management of Patients with Acute Coronary Syndromes, which recommends more aggressive treatment to achieve LDL-C targets 6 The updated label removes the requirement for Leqvio to be used on top of or in combination with statin therapy 1
Whats better: Leqvio vs Repatha? - meds. is In the Leqvio vs Repatha comparison, both medications have been shown to be effective in reducing LDL cholesterol levels However, Leqvio has been shown to have a more significant impact on reducing cardiovascular events, such as heart attacks and strokes
FDA approves label expansion for Novartis’ Leqvio Additional label updates include the removal of the “Limitations of Use” statement and four adverse events, following the updated data from the VictORION cardiovascular clinical trial programme
FDA Approves Inclisiran (Leqvio) Label Update as First-Line Monotherapy . . . The July 2025 label update removes the requirement to be used on top of or in combination with statin therapy, with additional updates including the revision of "primary hyperlipidemia" to "hypercholesterolemia" throughout the label to enhance focus on LDL-C reduction